Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

China · Delayed Price · Currency is CNY

44.64

+0.57 (1.29%)

Jul 31, 2026, 3:00 PM CST

Hangzhou Alltest Biotech Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	892.24	905.34	866.58	754.7	3,389	1,873
Revenue Growth	1.95%	4.47%	14.82%	-77.73%	80.88%	64.98%
Gross Profit	444.4	456.99	473.77	374.04	1,826	1,030
Operating Income	146.62	176.14	240.6	99.01	1,354	837.67
Net Income	178.37	220.19	302.47	180.58	1,185	765.69
Earnings Per Share	2.24	2.78	3.82	2.28	14.95	10.24
EPS Growth	-44.40%	-27.22%	67.54%	-84.75%	46.05%	-9.93%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	63.01
Overseas	836.44
Total	899.45

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	2,236	2,392	2,578	2,789	3,815	2,960
Total Debt	7.35	7.41	4.1	23.91	21.77	37.36
Net Cash (Debt)	2,229	2,385	2,574	2,765	3,793	2,922
Net Cash Growth	-12.38%	-7.34%	-6.92%	-27.10%	29.80%	317.07%
Net Cash Per Share	28.02	30.11	32.50	34.91	47.86	39.07

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	163.67	206.59	329.52	24.76	1,361	923.87
Capital Expenditures	-157.83	-219.1	-220.65	-533.49	-270.24	-140.12
Free Cash Flow	5.84	-12.5	108.87	-508.73	1,090	783.75
Free Cash Flow Growth	-91.32%	-	-	-	39.13%	33.84%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	49.81%	50.48%	54.67%	49.56%	53.87%	54.96%
Operating Margin	16.43%	19.46%	27.76%	13.12%	39.97%	44.71%
Pretax Margin	23.36%	27.74%	40.12%	26.16%	40.77%	47.80%
Profit Margin	19.99%	24.32%	34.90%	23.93%	34.97%	40.87%
FCF Margin	0.65%	-1.38%	12.56%	-67.41%	32.18%	41.84%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 3, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	2.000	2.000	3.000	1.500	6.757	2.703
Dividend Per Share Growth	-33.33%	-33.33%	100.00%	-77.80%	150.00%	99.99%
Dividend Yield	4.48%	3.20%	5.02%	2.44%	11.84%	4.14%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 3, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	19.90	22.72	16.23	29.69	4.66	8.66
P/FCF Ratio	591.64	-	45.10	-	5.06	8.46
PS Ratio	3.87	5.53	5.67	7.10	1.63	3.54